Diana I. Abdulganieva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Diana I. Abdulganieva has a total of 715 co-authors. Here are the top co-authors by number of shared publications:
- Dilyara D. Mukhametova
Kazan State Medical University
17 shared publications - Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
13 shared publications - Igor G. Bakulin
Mechnikov North-Western State Medical University Ministry of Health of the Russian Federation
13 shared publications - Svetlana Lapshina
Kazan State Medical University, Ministry of Health of Russia
13 shared publications - Igor Veniaminovich Maev
Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia
11 shared publications - Inna Z. Gaydukova
Mechnikov North-West State Medical University, St. Petersburg, Russia
11 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 24-33
Pharmacoeconomic study of tocilizumab dosing strategies as an intravenous solution in rheumatoid arthritis
Tocilizumab (TCZ) is widely used in rheumatoid arthritis (RA) and may be administered using different dosing regimens, including the standard dose (SD) of 8 mg/kg and regimens involving dose reduction or escalation depending on the clinical response. Under current healthcare conditions, assessment of the clinical and economic feasibility of drug-dosing strategies is particularly relevant. Objective : to evaluate, from the perspective of the Russian healthcare system, the clinical and economic feasibility of a TCZ dose de-escalation strategy (DDS) from 8 to 4 mg/kg after remission is achieved and a dose escalation strategy (DES) from 4 to 8 mg/kg if remission is not achieved, compared with the SD of 8 mg/kg in patients with RA. Material and methods . A decision-tree model with 1and 3-year time horizons was developed to compare the three TCZ dosing strategies. Costminimization analysis, budget impact analysis, and one-way sensitivity analysis were performed. Results and discussion . Over a 1-year time horizon, DES provided savings of 169,850 rubles (28.1%) per patient compared with SD, whereas DDS provided savings of 58,188 rubles (9.6%). Over a 3-year time horizon, savings amounted to 168,849 rubles (10.3%) and 95,848 rubles (5.8%) for DES and DDS, respectively. According to the budget impact analysis, transferring a proportion of patients to DES could reduce costs by 1.0–1.7 billion rubles over 3 years, whereas transition to DDS could reduce costs by 0.6–1.0 billion rubles. Conclusion . Within the adopted assumptions, the model demonstrates a potential reduction in direct drug costs when using strategies involving controlled dose reduction or initiation at a lower dose followed by escalation. Owing to the limited availability of direct comparative data and regulatory restrictions in the Russian Federation, the results should be regarded as a scenario-based pharmacoeconomic assessment requiring validation using Russian data.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 24-33
Open AccessPharmacoeconomic study of tocilizumab dosing strategies as an intravenous solution in rheumatoid arthritis
Tocilizumab (TCZ) is widely used in rheumatoid arthritis (RA) and may be administered using different dosing regimens, including the standard dose (SD) of 8 mg/kg and regimens involving dose reduction or escalation depending on the clinical response. Under current healthcare conditions, assessment of the clinical and economic feasibility of drug-dosing strategies is particularly relevant. Objective : to evaluate, from the perspective of the Russian healthcare system, the clinical and economic feasibility of a TCZ dose de-escalation strategy (DDS) from 8 to 4 mg/kg after remission is achieved and a dose escalation strategy (DES) from 4 to 8 mg/kg if remission is not achieved, compared with the SD of 8 mg/kg in patients with RA. Material and methods . A decision-tree model with 1and 3-year time horizons was developed to compare the three TCZ dosing strategies. Costminimization analysis, budget impact analysis, and one-way sensitivity analysis were performed. Results and discussion . Over a 1-year time horizon, DES provided savings of 169,850 rubles (28.1%) per patient compared with SD, whereas DDS provided savings of 58,188 rubles (9.6%). Over a 3-year time horizon, savings amounted to 168,849 rubles (10.3%) and 95,848 rubles (5.8%) for DES and DDS, respectively. According to the budget impact analysis, transferring a proportion of patients to DES could reduce costs by 1.0–1.7 billion rubles over 3 years, whereas transition to DDS could reduce costs by 0.6–1.0 billion rubles. Conclusion . Within the adopted assumptions, the model demonstrates a potential reduction in direct drug costs when using strategies involving controlled dose reduction or initiation at a lower dose followed by escalation. Owing to the limited availability of direct comparative data and regulatory restrictions in the Russian Federation, the results should be regarded as a scenario-based pharmacoeconomic assessment requiring validation using Russian data.
- Open Access
- 21 May 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (2) , 113-116
Intestinal Ultrasound in the Diagnosis of Crohn’s Disease of the Ileoanal Pouch: A Clinical Case
Aim : to demonstrate the utility of ultrasound in evaluating of Crohn’s disease with multiple extraintestinal manifestations after restorative proctocolectomy. Key points: Patient S., a 40-year-old female, was admitted to the clinic presenting with frequent bloody stools, abdominal pain in left lower quadrant and fever. She had a history of ulcerative colitis diagnosed in 2005. In 2021, the disease was complicated by toxic megacolon requiring a colectomy and an end ileostomy. In 2022, the second stage of surgical treatment was performed: proctectomy with ileal pouch-anal anastomosis. In 2023, the patient developed extraintestinal manifestations: aphthous stomatitis, erythema nodosum, and left ankle arthritis. Examination revealed ultrasound signs of Crohn’s disease: significant thickening of the bowel wall (predominantly of the muscularis propria and submucosa) with loss of wall stratification, as well as pathological vascularization of the ileoanal anastomosis, indicating transmural inflammation. Ileoscopy revealed linear ulcers, and histology showed inflammatory infiltration extending to the muscular layer, confirming the diagnosis of Crohn’s disease. Therapy with ustekinumab was initiated with positive clinical response and disease remission. Conclusion . Ultrasound has revealed signs of transmural inflammation of the ileal pouch and allowed to suspect Crohn’s disease, which has been subsequently confirmed by endoscopic and histological examinations.
- 21 May 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (2) , 113-116
Open AccessIntestinal Ultrasound in the Diagnosis of Crohn’s Disease of the Ileoanal Pouch: A Clinical Case
Aim : to demonstrate the utility of ultrasound in evaluating of Crohn’s disease with multiple extraintestinal manifestations after restorative proctocolectomy. Key points: Patient S., a 40-year-old female, was admitted to the clinic presenting with frequent bloody stools, abdominal pain in left lower quadrant and fever. She had a history of ulcerative colitis diagnosed in 2005. In 2021, the disease was complicated by toxic megacolon requiring a colectomy and an end ileostomy. In 2022, the second stage of surgical treatment was performed: proctectomy with ileal pouch-anal anastomosis. In 2023, the patient developed extraintestinal manifestations: aphthous stomatitis, erythema nodosum, and left ankle arthritis. Examination revealed ultrasound signs of Crohn’s disease: significant thickening of the bowel wall (predominantly of the muscularis propria and submucosa) with loss of wall stratification, as well as pathological vascularization of the ileoanal anastomosis, indicating transmural inflammation. Ileoscopy revealed linear ulcers, and histology showed inflammatory infiltration extending to the muscular layer, confirming the diagnosis of Crohn’s disease. Therapy with ustekinumab was initiated with positive clinical response and disease remission. Conclusion . Ultrasound has revealed signs of transmural inflammation of the ileal pouch and allowed to suspect Crohn’s disease, which has been subsequently confirmed by endoscopic and histological examinations.
- 21 May 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (2)
The Combination of Anxiety and Depressive Disorders in Patients with Irritable Bowel Syndrome (Literature Review and Expert Council Resolution)
Aim : to review current understanding of the role of intestinal microbiota in the pathogenesis of irritable bowel syndrome (IBS), anxiety and depressive disorders, and to present the materials of the Expert Council, which met on April 19, 2025, in Moscow. Key points. A likely unifying factor in the development of IBS, anxiety, and depressive disorders is a change in the composition of the intestinal microbiota, which causes disruption of neuroendocrine, immune, and metabolic signaling pathways of interaction between the gut and brain (components of the gut-brain axis). The intestinal microbiota plays a coordinating role in maintaining the physiological constancy of these pathways. However, when its composition is disrupted, pathogenic mechanisms are activated, leading to the combined development of both IBS and anxiety and depressive disorders. Recent data have shown that patients with IBS, as well as those suffering from anxiety and depressive disorders, exhibit a unidirectional change in the composition of the intestinal microbiota, characterized by a decrease in the number of Bifidobacterium bacteria , suggesting their key role in the pathogenesis of these diseases. A pathogenetically substantiated therapeutic strategy for the combination of IBS and mental disorders includes modifying the gut microbiota using strain-specific pro biotics containing Bifidobacterium type species. Bifidobacterium longum 35624 and Bifidobacterium longum 1714 strains have demonstrated clinical efficacy in reducing the severity of IBS symptoms, anxiety, and depression. Conclusion . Prescribing a combination of Bifidobacterium longum 35624 and Bifidobacterium longum 1714 probiotic strains to patients with IBS, including those with comorbid mental disorders, is clinically justified. This combination of strains holds promise for inclusion in clinical guidelines for the management of patients with irritable bowel syndrome and mental and behavioral disorders.
- 21 May 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (2)
The Combination of Anxiety and Depressive Disorders in Patients with Irritable Bowel Syndrome (Literature Review and Expert Council Resolution)
Aim : to review current understanding of the role of intestinal microbiota in the pathogenesis of irritable bowel syndrome (IBS), anxiety and depressive disorders, and to present the materials of the Expert Council, which met on April 19, 2025, in Moscow. Key points. A likely unifying factor in the development of IBS, anxiety, and depressive disorders is a change in the composition of the intestinal microbiota, which causes disruption of neuroendocrine, immune, and metabolic signaling pathways of interaction between the gut and brain (components of the gut-brain axis). The intestinal microbiota plays a coordinating role in maintaining the physiological constancy of these pathways. However, when its composition is disrupted, pathogenic mechanisms are activated, leading to the combined development of both IBS and anxiety and depressive disorders. Recent data have shown that patients with IBS, as well as those suffering from anxiety and depressive disorders, exhibit a unidirectional change in the composition of the intestinal microbiota, characterized by a decrease in the number of Bifidobacterium bacteria , suggesting their key role in the pathogenesis of these diseases. A pathogenetically substantiated therapeutic strategy for the combination of IBS and mental disorders includes modifying the gut microbiota using strain-specific pro biotics containing Bifidobacterium type species. Bifidobacterium longum 35624 and Bifidobacterium longum 1714 strains have demonstrated clinical efficacy in reducing the severity of IBS symptoms, anxiety, and depression. Conclusion . Prescribing a combination of Bifidobacterium longum 35624 and Bifidobacterium longum 1714 probiotic strains to patients with IBS, including those with comorbid mental disorders, is clinically justified. This combination of strains holds promise for inclusion in clinical guidelines for the management of patients with irritable bowel syndrome and mental and behavioral disorders.
- Open Access
- 5 May 2026
- Published by Alfmed LLC in Medical alphabet
- No. 5,p. 54-60
Adipose tissue status in patients with inflammatory bowel disease: diagnostic challenges and clinical significance
The aim of this study. To compare different methods of adipose tissue assessment (body mass index (BMI), bioelectrical impedance analysis (BIA), ultrasound (US)) in patients with inflammatory bowel disease (IBD). Materials and methods. The study included 136 patients with IBD (62 with ulcerative colitis, 74 with Crohn's disease) and 30 control subjects. All participants underwent anthropometry (BMI, circumferences), handgrip strength measurement, BIA, and adipose tissue ultrasound according to a standardized protocol. Results. According to BMI, overweight and obesity were found in 28.7 % of IBD patients. BIA revealed excess fat mass in 31.9 % of patients; notably, 30.2 % of these individuals had a normal BMI. Ultrasound detected increased adipose tissue in 47.3 % of patients, allowing for differentiation of obesity types. Excess fat was found by ultrasound in 44 % of patients with normal BMI. A negative correlation was found between fat mass percentage and handgrip strength (r= –0.363; pConclusions. There is a need to include instrumental methods for assessing body composition in the examination algorithms for patients with IBD for timely correction of nutritional status and prevention of complications. The high prevalence of excess fat mass and its association with decreased muscle strength (dynapenia) justify the need for screening for sarcopenic obesity in patients with IBD.
- 5 May 2026
- Published by Alfmed LLC in Medical alphabet
- No. 5,p. 54-60
Open AccessAdipose tissue status in patients with inflammatory bowel disease: diagnostic challenges and clinical significance
The aim of this study. To compare different methods of adipose tissue assessment (body mass index (BMI), bioelectrical impedance analysis (BIA), ultrasound (US)) in patients with inflammatory bowel disease (IBD). Materials and methods. The study included 136 patients with IBD (62 with ulcerative colitis, 74 with Crohn's disease) and 30 control subjects. All participants underwent anthropometry (BMI, circumferences), handgrip strength measurement, BIA, and adipose tissue ultrasound according to a standardized protocol. Results. According to BMI, overweight and obesity were found in 28.7 % of IBD patients. BIA revealed excess fat mass in 31.9 % of patients; notably, 30.2 % of these individuals had a normal BMI. Ultrasound detected increased adipose tissue in 47.3 % of patients, allowing for differentiation of obesity types. Excess fat was found by ultrasound in 44 % of patients with normal BMI. A negative correlation was found between fat mass percentage and handgrip strength (r= –0.363; pConclusions. There is a need to include instrumental methods for assessing body composition in the examination algorithms for patients with IBD for timely correction of nutritional status and prevention of complications. The high prevalence of excess fat mass and its association with decreased muscle strength (dynapenia) justify the need for screening for sarcopenic obesity in patients with IBD.
- Open Access
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 49-60
Assessment of the prevalence of systemic lupus erythematosus in women with reproductive health problems in the Russian Federation. Results of the multicenter pilot PRISMA study
Objective: to assess the prevalence of systemic lupus erythematosus (SLE) in the Russian population of patients with reproductive health problems (RHP). Material and methods. Patients were enrolled in 2023–2024 at 15 clinical centers in 5 federal districts of the Russian Federation. Women referred by a gynecologist, reproductive specialist, or general practitioner to a rheumatologist to rule out a systemic autoimmune rheumatic disease (SARD) were included. The study comprised two visits: the first screening visit and the second (final, 2–6 weeks later) visit, during which SARD verification was performed. Descriptive statistics methods were used for data analysis. The frequency of features in two independent study groups was compared using χ2 (Pearson’s test), odds ratios with 95% confidence intervals. The association between antibody levels and clinical manifestations was assessed by constructing a regression model. Results and discussion. Of 631 women examined, 612 (97.0%) met the inclusion criteria; 19 women were excluded because they did not have RHP (infertility or pregnancy loss) and/or signs of SARD. Antinuclear factor (ANF) was determined in 590 of 612 women. ANF positivity was detected in 238 (40.3%) of 590 patients. Of these 238 women, antinuclear antibodies were detected in 71, and decreased complement component levels were found in 55 (C3 in 28 and C4 in 27). SARD was diagnosed in 71 (11.6%) cases: SLE in 27 (4.4%) (definite in 23 and probable/incomplete in 4), mixed connective tissue disease was newly diagnosed in 36 (5.9%), Sjцgren’s disease in 4 (0.7%), and systemic sclerosis in 4 (0.7%). Among ANF-positive patients with RHP, 167 (70.2%) of 238 had no SARD. Conclusion. In this multicenter pilot study, the frequency of SLE in the Russian population among women with RHP was 4.4% (27 of 612 women), and the overall frequency of SARD was 11.6% (71 of 612). ANF positivity occurred more than three times (40.3%) more often than newly diagnosed SARD cases, indicating the need for further studies to clarify the reasons for ANF occurrence in women of childbearing age with RHP and for their longitudinal follow-up.
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 49-60
Open AccessAssessment of the prevalence of systemic lupus erythematosus in women with reproductive health problems in the Russian Federation. Results of the multicenter pilot PRISMA study
Objective: to assess the prevalence of systemic lupus erythematosus (SLE) in the Russian population of patients with reproductive health problems (RHP). Material and methods. Patients were enrolled in 2023–2024 at 15 clinical centers in 5 federal districts of the Russian Federation. Women referred by a gynecologist, reproductive specialist, or general practitioner to a rheumatologist to rule out a systemic autoimmune rheumatic disease (SARD) were included. The study comprised two visits: the first screening visit and the second (final, 2–6 weeks later) visit, during which SARD verification was performed. Descriptive statistics methods were used for data analysis. The frequency of features in two independent study groups was compared using χ2 (Pearson’s test), odds ratios with 95% confidence intervals. The association between antibody levels and clinical manifestations was assessed by constructing a regression model. Results and discussion. Of 631 women examined, 612 (97.0%) met the inclusion criteria; 19 women were excluded because they did not have RHP (infertility or pregnancy loss) and/or signs of SARD. Antinuclear factor (ANF) was determined in 590 of 612 women. ANF positivity was detected in 238 (40.3%) of 590 patients. Of these 238 women, antinuclear antibodies were detected in 71, and decreased complement component levels were found in 55 (C3 in 28 and C4 in 27). SARD was diagnosed in 71 (11.6%) cases: SLE in 27 (4.4%) (definite in 23 and probable/incomplete in 4), mixed connective tissue disease was newly diagnosed in 36 (5.9%), Sjцgren’s disease in 4 (0.7%), and systemic sclerosis in 4 (0.7%). Among ANF-positive patients with RHP, 167 (70.2%) of 238 had no SARD. Conclusion. In this multicenter pilot study, the frequency of SLE in the Russian population among women with RHP was 4.4% (27 of 612 women), and the overall frequency of SARD was 11.6% (71 of 612). ANF positivity occurred more than three times (40.3%) more often than newly diagnosed SARD cases, indicating the need for further studies to clarify the reasons for ANF occurrence in women of childbearing age with RHP and for their longitudinal follow-up.
- Open Access
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 42-48
Atlantoaxial joint involvement in rheumatoid arthritis: clinical and imaging features
Objective: to study clinical and imaging characteristics in patients with rheumatoid arthritis (RA) with atlantoaxial joint involvement. Material and methods. A total of 60 patients with RA were examined; mean age was 53.6±12.4 years. Median DAS28-CRP was 5.1 [4.8; 5.3], and median disease duration was 120 [66; 300] months. Extended clinical assessment included evaluation of neurological status, components of neuropathic pain and central sensitization, quality of life, and the degree of functional impairment. Magnetic resonance imaging (MRI) of the craniovertebral junction (CVJ) was performed with assessment of structural changes and measurement of five craniometric parameters to detect displacement of the CII odontoid process. Results and discussion. Clinical signs of cervical spine (C-spine) involvement were present in 91.7% of patients: neck and head pain, varying degrees of activity limitation due to neck pain, and neurological manifestations. MRI revealed CVJ changes in 90% (n=54) of patients: structural abnormalities in 81.7% and displacement of the CII odontoid process in 68.3%. The strongest correlations of structural changes were found with the presence of neck pain, low quality-of-life scores (EQ-5D), high RA activity, peripheral joint erosions on radiographs, arterial hypertension, high body mass index, and the absence of systemic manifestations of the disease. Craniometric abnormalities were associated (pConclusion. Based on the study, the risk factors for C-spine involvement in RA patients are neck pain, certain features of the RA course, comorbidity, functional limitations (HAQ), and low quality of life (EQ-5D).
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 42-48
Open AccessAtlantoaxial joint involvement in rheumatoid arthritis: clinical and imaging features
Objective: to study clinical and imaging characteristics in patients with rheumatoid arthritis (RA) with atlantoaxial joint involvement. Material and methods. A total of 60 patients with RA were examined; mean age was 53.6±12.4 years. Median DAS28-CRP was 5.1 [4.8; 5.3], and median disease duration was 120 [66; 300] months. Extended clinical assessment included evaluation of neurological status, components of neuropathic pain and central sensitization, quality of life, and the degree of functional impairment. Magnetic resonance imaging (MRI) of the craniovertebral junction (CVJ) was performed with assessment of structural changes and measurement of five craniometric parameters to detect displacement of the CII odontoid process. Results and discussion. Clinical signs of cervical spine (C-spine) involvement were present in 91.7% of patients: neck and head pain, varying degrees of activity limitation due to neck pain, and neurological manifestations. MRI revealed CVJ changes in 90% (n=54) of patients: structural abnormalities in 81.7% and displacement of the CII odontoid process in 68.3%. The strongest correlations of structural changes were found with the presence of neck pain, low quality-of-life scores (EQ-5D), high RA activity, peripheral joint erosions on radiographs, arterial hypertension, high body mass index, and the absence of systemic manifestations of the disease. Craniometric abnormalities were associated (pConclusion. Based on the study, the risk factors for C-spine involvement in RA patients are neck pain, certain features of the RA course, comorbidity, functional limitations (HAQ), and low quality of life (EQ-5D).
- Open Access
- 26 February 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 12,p. 88-102
The problem of sarcopenia in patients with infl ammatory bowel disease: a review
Aim: to highlight the problem of sarcopenia among patients with inflammatory bowel diseases (IBD). Key points. In 2019, EWGSOP2 hypothesized that sarcopenia is promoted by many contributing factors including inflammatory bowel diseases (ulcerative colitis and Crohn’s disease). Article presented current hypotheses of the pathogenesis of sarcopenia in patients with IBD, with an emphasis on malnutrition, chronic inflammation, and intestinal dysbiosis. Current methods for diagnosing sarcopenia in patients with IBD are presented. The problem of sarcopenic obesity is separately described. Particular attention is paid to the influence of biological agents on the state of muscles. Although data on sarcopenia in IBD are limited, the available studies suggest the need for a comprehensive approach to assessment, early detection and interventions targeted on inflammation, malnutrition, and muscle wasting. And this is a key component of comprehensive strategies for the management of IBD-associated sarcopenia. Conclusion: The interaction between IBD and sarcopenia represents a significant clinical problem with profound implications for treatment outcomes.
- 26 February 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 12,p. 88-102
Open AccessThe problem of sarcopenia in patients with infl ammatory bowel disease: a review
Aim: to highlight the problem of sarcopenia among patients with inflammatory bowel diseases (IBD). Key points. In 2019, EWGSOP2 hypothesized that sarcopenia is promoted by many contributing factors including inflammatory bowel diseases (ulcerative colitis and Crohn’s disease). Article presented current hypotheses of the pathogenesis of sarcopenia in patients with IBD, with an emphasis on malnutrition, chronic inflammation, and intestinal dysbiosis. Current methods for diagnosing sarcopenia in patients with IBD are presented. The problem of sarcopenic obesity is separately described. Particular attention is paid to the influence of biological agents on the state of muscles. Although data on sarcopenia in IBD are limited, the available studies suggest the need for a comprehensive approach to assessment, early detection and interventions targeted on inflammation, malnutrition, and muscle wasting. And this is a key component of comprehensive strategies for the management of IBD-associated sarcopenia. Conclusion: The interaction between IBD and sarcopenia represents a significant clinical problem with profound implications for treatment outcomes.
- Open Access
- 23 February 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (6) , 27-34
Artificial Intelligence in Ultrasound Diagnosis of Bowel Diseases: Modern Possibilities
Aim. Review of current achievements, opportunities and challenges in applying artificial intelligence (AI) for analyzing intestinal ultrasound images. Key points. Ultrasound examination is a highly informative, safe, and widely accessible method for bowel pathology diagnosis. The integration of AI, particularly deep learning and radiomics methods, aims to overcome the operator-dependence of ultrasound, standardize diagnosis, and enhance its efficiency. This article reviews the development and validation of AI algorithms for key areas: inflammatory bowel diseases, acute appendicitis, bowel intussusception and colorectal cancer. Limitations and concerns that require resolution for the successful integration of AI into clinical practice are also discussed. Conclusion. The integration of AI into ultrasound diagnosis of bowel diseases has significant potency for improving accuracy, reproducibility, and operational efficiency.
- 23 February 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (6) , 27-34
Open AccessArtificial Intelligence in Ultrasound Diagnosis of Bowel Diseases: Modern Possibilities
Aim. Review of current achievements, opportunities and challenges in applying artificial intelligence (AI) for analyzing intestinal ultrasound images. Key points. Ultrasound examination is a highly informative, safe, and widely accessible method for bowel pathology diagnosis. The integration of AI, particularly deep learning and radiomics methods, aims to overcome the operator-dependence of ultrasound, standardize diagnosis, and enhance its efficiency. This article reviews the development and validation of AI algorithms for key areas: inflammatory bowel diseases, acute appendicitis, bowel intussusception and colorectal cancer. Limitations and concerns that require resolution for the successful integration of AI into clinical practice are also discussed. Conclusion. The integration of AI into ultrasound diagnosis of bowel diseases has significant potency for improving accuracy, reproducibility, and operational efficiency.
- Open Access
- 29 December 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (6) , 619-628
The impact of clinical and demographic factors on the efficacy of divozilimab in patients with systemic sclerosis: Post hoc analysis of the randomized, double-blind, placebo-controlled phase III clinical trial LIBERIUS
Divozilimab (DIV) is a new monoclonal antibody drug against CD20, which has demonstrated efficacy and safety in patients with systemic sclerosis (SS) in terms of reducing skin fibrosis and stabilizing lung function. The aim of the study was to assess the dynamics of skin fibrosis according to the mRSS in SSD patients treated DIV with depending on gender, disease duration and initial lung function. Material and methods . A post hoc analysis of data from a 48-week randomized placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS was conducted. 151 patients with SS were randomized into groups treated with DIV (n=76) or Placebo (n=75). DIV was administered intravenously at 250 mg on weeks 0 and 2, and then at 500 mg once every 24 weeks. The efficacy of DIV compared to placebo in terms of reducing skin fibrosis according to the mRSS was evaluated in subgroups of patients formed by gender (female/male), disease duration at the time of therapy initiation (less than 3 years, from 3 to 5 years, and more than 5 years), as well as by initial lung function (forced vital capacity (FVC) % predicted ≥80%/Results . The average change in mRSS from baseline at week 48 in men was –6.1±2.1 in the DIV and 1.6±6.2 in Placebo (LS mean difference (LSMD) –7.5 (95% CI: –11.6; –3.4); p=0.0004). In the subgroup of women, the change in mRSS was –5.1±4.1 and –2.5±4.4 in the DIV and Placebo groups respectively (LSMD=–2.5 (95% CI: –4.0; –1.0); p=0.001). In patients with a SS duration of up to 3 years, the mRSS dynamics was the most pronounced: –5.6±4.0 in DIV compared to –0.7±6.0 in placebo (LSMD=–5.2 (95% CI: –7.4; –2.9); pConclusion . DIV is a promising and effective therapeutic option for all patients with SS, regardless of gender, although a more pronounced effect on reducing skin fibrosis can be expected in men. DIV therapy is appropriate at any SS duration, but the highest efficacy in terms of skin fibrosis is observed in patients with recently developed disease. A significant and marked reduction in skin score in patients with initially normal and reduced lung function defines the possibility of DIV therapy in a broad population of SS patients. This is promising for improving the visceral lesions prognosis during DIV therapy, especially in the case of early therapy.
- 29 December 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (6) , 619-628
Open AccessThe impact of clinical and demographic factors on the efficacy of divozilimab in patients with systemic sclerosis: Post hoc analysis of the randomized, double-blind, placebo-controlled phase III clinical trial LIBERIUS
Divozilimab (DIV) is a new monoclonal antibody drug against CD20, which has demonstrated efficacy and safety in patients with systemic sclerosis (SS) in terms of reducing skin fibrosis and stabilizing lung function. The aim of the study was to assess the dynamics of skin fibrosis according to the mRSS in SSD patients treated DIV with depending on gender, disease duration and initial lung function. Material and methods . A post hoc analysis of data from a 48-week randomized placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS was conducted. 151 patients with SS were randomized into groups treated with DIV (n=76) or Placebo (n=75). DIV was administered intravenously at 250 mg on weeks 0 and 2, and then at 500 mg once every 24 weeks. The efficacy of DIV compared to placebo in terms of reducing skin fibrosis according to the mRSS was evaluated in subgroups of patients formed by gender (female/male), disease duration at the time of therapy initiation (less than 3 years, from 3 to 5 years, and more than 5 years), as well as by initial lung function (forced vital capacity (FVC) % predicted ≥80%/Results . The average change in mRSS from baseline at week 48 in men was –6.1±2.1 in the DIV and 1.6±6.2 in Placebo (LS mean difference (LSMD) –7.5 (95% CI: –11.6; –3.4); p=0.0004). In the subgroup of women, the change in mRSS was –5.1±4.1 and –2.5±4.4 in the DIV and Placebo groups respectively (LSMD=–2.5 (95% CI: –4.0; –1.0); p=0.001). In patients with a SS duration of up to 3 years, the mRSS dynamics was the most pronounced: –5.6±4.0 in DIV compared to –0.7±6.0 in placebo (LSMD=–5.2 (95% CI: –7.4; –2.9); pConclusion . DIV is a promising and effective therapeutic option for all patients with SS, regardless of gender, although a more pronounced effect on reducing skin fibrosis can be expected in men. DIV therapy is appropriate at any SS duration, but the highest efficacy in terms of skin fibrosis is observed in patients with recently developed disease. A significant and marked reduction in skin score in patients with initially normal and reduced lung function defines the possibility of DIV therapy in a broad population of SS patients. This is promising for improving the visceral lesions prognosis during DIV therapy, especially in the case of early therapy.
- Open Access
- 25 December 2025
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 22 (4) , 134-138
Features of myocardial involvement in patients with psoriatic arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis and an increased risk of cardiovascular complications. Systemic inflammation and excessive production of proinflammatory cytokines contribute to myocardial remodeling and the development of subclinical dysfunction. Of particular interest is the relationship between joint inflammatory changes and cardiac dysfunction in PsA. Objective: To determine the features of myocardial involvement in patients with psoriatic arthritis depending on joint changes. Materials and methods: A total of 74 patients with PsA, 43 men, 31 women; mean age (50.5 ± 12.4) years, who received outpatient and inpatient treatment were examined. All patients underwent standard laboratory tests, transthoracic echocardiography with pulsed-wave and tissue Doppler imaging, as well as ultrasound examination of the joints. Echocardiography assessed systolic and diastolic function, left ventricular (LV) mass, and geometry. Synovitis and enthesitis were identified by joint ultrasound. Statistical analysis was performed using standard methods, with significance set at p 0.05. Results: Disease duration correlated with impaired diastolic function of both ventricles. High disease activity according to the DAPSA index and elevated C-reactive protein levels were associated with reduced LV ejection fraction. The presence of synovitis and enthesitis was accompanied by increased myocardial mass and signs of diastolic dysfunction. Conclusions: In patients with PsA, a relationship was established between joint inflammatory changes and cardiac dysfunction, highlighting the need for comprehensive monitoring to ensure early detection of cardiovascular complications.
- 25 December 2025
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 22 (4) , 134-138
Open AccessFeatures of myocardial involvement in patients with psoriatic arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis and an increased risk of cardiovascular complications. Systemic inflammation and excessive production of proinflammatory cytokines contribute to myocardial remodeling and the development of subclinical dysfunction. Of particular interest is the relationship between joint inflammatory changes and cardiac dysfunction in PsA. Objective: To determine the features of myocardial involvement in patients with psoriatic arthritis depending on joint changes. Materials and methods: A total of 74 patients with PsA, 43 men, 31 women; mean age (50.5 ± 12.4) years, who received outpatient and inpatient treatment were examined. All patients underwent standard laboratory tests, transthoracic echocardiography with pulsed-wave and tissue Doppler imaging, as well as ultrasound examination of the joints. Echocardiography assessed systolic and diastolic function, left ventricular (LV) mass, and geometry. Synovitis and enthesitis were identified by joint ultrasound. Statistical analysis was performed using standard methods, with significance set at p 0.05. Results: Disease duration correlated with impaired diastolic function of both ventricles. High disease activity according to the DAPSA index and elevated C-reactive protein levels were associated with reduced LV ejection fraction. The presence of synovitis and enthesitis was accompanied by increased myocardial mass and signs of diastolic dysfunction. Conclusions: In patients with PsA, a relationship was established between joint inflammatory changes and cardiac dysfunction, highlighting the need for comprehensive monitoring to ensure early detection of cardiovascular complications.